"Strengthening of the company's patent portfolio with this grant by the USPTO is timely and perfectly aligned with recent efforts to take the CIZ1B ELISA test format to market with our US partner Cizzle Bio," Dawn Coverley, Chief Scientific Officer of Cizzle Biotechnology, said.